+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gastroesophageal Reflux Disease (GERD) Therapeutics - Global Strategic Business Report

  • PDF Icon

    Report

  • 93 Pages
  • April 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5302624

Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market to Reach $7.8 Billion by 2030

The global market for Gastroesophageal Reflux Disease (GERD) Therapeutics estimated at US$5.8 Billion in the year 2022, is projected to reach a revised size of US$7.8 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2022-2030. Antacids, one of the segments analyzed in the report, is projected to record 4.9% CAGR and reach US$3.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the H2 Receptor Blockers segment is readjusted to a revised 3.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 6.5% CAGR

The Gastroesophageal Reflux Disease (GERD) Therapeutics market in the U.S. is estimated at US$1.6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2% and 3.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Select Competitors (Total 42 Featured) -

  • Abbott
  • AstraZeneca PLC
  • Daewoong Pharmaceutical Co., Ltd
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • RaQualia Pharma, Inc.
  • Reckitt Benckiser Group PLC
  • SFJ Pharmaceuticals Group
  • SRS Pharmaceuticals Pvt., Ltd
  • Takeda Pharmaceutical Co., Ltd.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Gastroesophageal Reflux Disease (GERD) Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Antacids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for H2 Receptor Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for H2 Receptor Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for H2 Receptor Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Proton Pump Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Pro-Kinetic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Pro-Kinetic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 15: World 16-Year Perspective for Pro-Kinetic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 16: World Gastroesophageal Reflux Disease (GERD) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 18: USA Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 19: USA 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
CANADA
  • Table 20: Canada Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: Canada Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: Canada 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
JAPAN
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 23: Japan Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 24: Japan Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: Japan 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
CHINA
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 26: China Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: China Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: China 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
EUROPE
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 29: Europe Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 30: Europe Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: Europe 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 32: Europe Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: Europe Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: Europe 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
FRANCE
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 35: France Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: France Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: France 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
GERMANY
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 38: Germany Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: Germany Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: Germany 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
ITALY
  • Table 41: Italy Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: Italy Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: Italy 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
UNITED KINGDOM
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 44: UK Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: UK Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: UK 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
SPAIN
  • Table 47: Spain Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: Spain Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: Spain 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
RUSSIA
  • Table 50: Russia Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Russia Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: Russia 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
REST OF EUROPE
  • Table 53: Rest of Europe Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: Rest of Europe Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: Rest of Europe 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
ASIA-PACIFIC
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 57: Asia-Pacific Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 58: Asia-Pacific 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
  • Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: Asia-Pacific Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 61: Asia-Pacific 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2023 & 2030
AUSTRALIA
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott
  • AstraZeneca PLC
  • Daewoong Pharmaceutical Co., Ltd
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • RaQualia Pharma, Inc.
  • Reckitt Benckiser Group PLC
  • SFJ Pharmaceuticals Group
  • SRS Pharmaceuticals Pvt., Ltd
  • Takeda Pharmaceutical Co., Ltd.

Table Information